They show slight increases in dystrophin, it’s just a case of where you draw the line and define “efficacy”. It’s thought that at least 10% of normal dystrophin levels are required for any noticeable improved physical effect, and the improvements caused by the drug still leave the child with less than 1% of normal levels.
I go back to a point I made over a year ago, in light of DMD parents signing a petition that influenced the FDA’s decision - what Sarepta are selling to parents of newly diagnosed DMD patients is “hope” at little expense to those who get full health coverage, and at a stage when the prognosis is horrible to contemplate, but not yet played out.
Parents would do anything to keep hope of a cure or just an improvement alive.
The EMA rejected the application.
- Forums
- ASX - By Stock
- For General Information
They show slight increases in dystrophin, it’s just a case of...
-
-
- There are more pages in this discussion • 247 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PER (ASX) to my watchlist
|
|||||
Last
8.4¢ |
Change
-0.001(1.18%) |
Mkt cap ! $75.72M |
Open | High | Low | Value | Volume |
8.4¢ | 8.4¢ | 8.3¢ | $3.097K | 37.23K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 29206 | 8.3¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
8.4¢ | 118557 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 29206 | 0.083 |
2 | 30500 | 0.082 |
2 | 58100 | 0.081 |
2 | 160300 | 0.080 |
1 | 100000 | 0.079 |
Price($) | Vol. | No. |
---|---|---|
0.084 | 118557 | 1 |
0.085 | 98557 | 2 |
0.086 | 6500 | 1 |
0.089 | 135000 | 2 |
0.090 | 386175 | 4 |
Last trade - 16.10pm 05/07/2024 (20 minute delay) ? |
Featured News
PER (ASX) Chart |